Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Oppenheimer cut their price objective on Cellectis from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, June 12th.

Cellectis Trading Down 4.3 %

Shares of Cellectis stock opened at $1.89 on Friday. The business has a fifty day simple moving average of $2.20 and a 200-day simple moving average of $2.39. The firm has a market cap of $105.28 million, a price-to-earnings ratio of -1.47 and a beta of 3.09. Cellectis has a fifty-two week low of $0.96 and a fifty-two week high of $3.77. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. The firm had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $6.00 million. Cellectis had a negative net margin of 401.83% and a negative return on equity of 78.90%. On average, equities analysts forecast that Cellectis will post -0.54 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

Several hedge funds have recently bought and sold shares of CLLS. Long Focus Capital Management LLC increased its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the period. Baillie Gifford & Co. grew its holdings in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock valued at $2,192,000 after acquiring an additional 10,605 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after acquiring an additional 12,467 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Cellectis in the second quarter worth $29,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.